Atlantic bridge 20217/5/2023 ![]() Westrup graduated Cum Laude from Wake Forest University with a BSc in Biology and received her medical degree with honours at University College Dublin. She is a member of the National Cancer Care Program, Melanoma Clinical Advisory Group. Westrup currently advises the Health Care Products Regulatory Clinical Sub Trials Committee. ![]() Her past research on breast cancer has been presented at international conferences, and is published in peer reviewed journals. Westrup is a member of Cancer Trials Ireland. Westrup lectures on the UCD Risk Management Program. She currently sits on the Clinical Governance Committee of the Beacon Hospital Board, and was an invited member of the International Quality and Patient Safety Committee of UPMC. Westrup was a member of the original Beacon Hospital Board from 2007 – 2008, served as Chairperson of the Beacon Pharmacy/Therapeutics Committee for 3 years, and as the Director of Education for Beacon Hospital from 2008 – 2014. ![]() ![]() Westrup is the former Medical Director at Beacon Hospital. Westrup is appointed Associate Clinical Professor at University College Dublin and sits on the steering committee of the innovative UCD Beacon Academy. Westrup is the Director of Oncology, and a Consultant Medical Oncologist at Beacon Hospital Dr. Helen is a fellow of the Institute of Engineers of Ireland, a past Chair of the Irish Medical Devices Association, and serves as a non-executive director of a number of companies.ĭr. Helen has a Bachelor of Engineering from NUI Galway, a Masters in Project Management from UL, and has completed a Senior Executive Programme at Stanford University. Prior to joining Creganna-Tactx in 2003, Helen worked with Medtronic and Tyco Healthcare (Covidien) in Product Development and R&D functional management roles. The organisation grew from 100 people at a single site in Galway to over 1,250 people across a global network of four sites in Ireland, the USA and Singapore. The expansion included three company acquisitions, a strategic joint venture in Asia, and the raising of significant debt and equity financing. During Helen’s time as CEO, the company grew five-fold to become the largest indigenous medical device company. The company is currently ranked among the world’s top 10 medical device outsource providers. Creganna-Tactx Medical is a global supplier to the medical device industry specialising in products, technologies and solutions for minimally invasive therapies. Helen Ryan was the Chief Executive Officer of Creganna-Tactx Medical from 2005 until September 2013. Helen was listed as one of the Top 100 Women in STEM in Ireland. Electronic Engineering Degree from UCD and was then awarded her PhD from The University of Edinburgh in the area of AI based conversational agents and multimodal interfaces. Helen also held the position of Sales Director at Celtrak Ltd (acquired by Thermo King, 2015). Prior to joining Atlantic Bridge, Helen was a member of the NDRC Investment Committee playing a key role in the allocation of €45m capital into new technology ventures with a particular focus health and ICT. Active in the early stage ecosystem Helen is also a board member to several companies and a mentor and advisor to organisations including Knowledge Transfer Ireland, UCD VentureLaunch, NDRC, TechIreland and TechInnovate. Helen is a Kauffman Fellow (Class 22, 2019) and in 2021 was nominated as VP of TechTour Deep Tech (Software). Having successfully sourced and financed dozens of IP rich technology ventures in software (enterprise, cloud, mobile), hardware (robotics, semiconductors) and life-sciences (medtech, diagnostics), Helen brings over 15 years’ experience in early stage investing. At Atlantic Bridge, Helen manages early stage investing and leads investments from University Fund I & II which are focused on early stage deeptech companies built from world class research generated at leading research institutions and universities. Helen joined Atlantic Bridge in 2015 on our University Bridge Fund.
0 Comments
Leave a Reply. |